VanEck Vectors Biotech ETF (BBH) - NYSEARCA
  • May 9, 2014, 9:59 AM
    • The downtrend in the biotech sector that began on February 26 ain't done yet. On a technical basis, (IBB +0.1%) has been trying to hold on to its wobbly base since its snap back move on April 15. Volume has dried up as the index struggles to stay above the key support level of the 200-day MA. This is not encouraging action for longs.
    • The relative strength line has dropped from a best-possible rating of 99 down to 68 with no upturn in sight.
    • Biotech investors should keep their powder dry until the money flow turns decidedly positive. Based on the chart, there is no indication that this is happening yet.
    • ETFs: XBI, BIB, BBH, FBT, PBE, BIS
    | May 9, 2014, 9:59 AM | 1 Comment
  • May 8, 2014, 7:35 AM
    • China intends to end price limits on low-cost drugs after the controls caused quality problems and shortages.
    • China's economic planning body, the National Development & Reform Commission, will lift price caps on 280 drugs provided by Western companies and 250 Chinese patent medicines.
    • Sanofi (SNY) and Pfizer (PFE) said it's too early to ascertain the impact of the new policy. Other companies that could be affected include GlaxoSmithKline (GSK).
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
    | May 8, 2014, 7:35 AM
  • Apr. 25, 2014, 2:49 PM
    • Much of the high tech equipment hospitals use can be easily hacked and could pose a significant danger to patients according to the head of information security at Essentia Health.
    • Imaging equipment, insulin pumps, defibrillators and refrigerators that store blood and drugs are examples of networked gear that have remote access control features.
    • The devices' software is plagued by common security holes like weak passwords, lack of authentication to access, easy-to-determine default and hard-coded passwords and embedded web servers and administrative interfaces that make it easy to identify and manipulate devices once found on the network.
    • Hospital are apparently just waking up to the potential risks.
    • Last spring, the FDA and DHS issued a notice to the health care industry about problems with hard-coded passwords after researchers found issues in ~300 devices.
    • ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Apr. 25, 2014, 2:49 PM
  • Apr. 25, 2014, 1:31 PM
    • Today's selloff is following the pattern of most in the past few weeks, with the small caps (IWM -1.9%) and tech (QQQ -1.5%) leading the way. Pacing declines in the Nasdaq are a 8.8% dive in Amazon post-earnings and a 4.6% fall in Facebook. Setting tongues wagging in FB - but hardly a huge deal - is the sale of another 283K shares by Sheryl Sandberg, bringing her holdings down to 8.7M shares.
    • The liquidation in biotech has previously been a convenient excuse for small cap selloffs, but the IBB is off just 1.4% today, outperforming the Russell 2000.
    • What's working? Utilities again. The XLU +0.8% today and +13% this year, outperforming the Russell 2000 by about 1.6K basis points.
    • Small cap ETFs: IWM, TZA, TNA, UWM, VB, IJR, SLY, RWJ, URTY, SCHA, TWM, RWM, SRTY, SAA, DWAS, VTWO, SDD, VIOO, JKJ, RSCO, SBB, FYX, XSLV, EWRS, TWOK, SMLV, PXSC
    • Utility ETFs: XLU, IDU, VPU, NLR, GRID, JXI, NUCL, DBU, IPU, UPW, RYU, PUI, FUTY, FXU, SDP, PSCU, UTLT
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Apr. 25, 2014, 1:31 PM | 7 Comments
  • Apr. 25, 2014, 12:46 PM
    • In what may be the first step in discovering how to eradicate African sleeping sickness, scientists decipher the dreaded tsetse fly's genome. The decade-long effort involved more than 149 scientists from 78 research institutions in 18 countries. It's genome contains ~12K genes and 366M letters of genetic code.
    • The fly carries the parasitic microorganism, Trypanosoma brucei, that causes Trypanosomiasis in 36 sub-Saharan countries. It transmits the pathogen in its saliva when it bites a victim. The disease is fatal if untreated.
    • The disease also afflicts cattle with a disease called Nagana.
    • The bug's biology is unusual. It gives birth to live young, it nourishes larvae inside the uterus with a milk-like substance, it finds the colors blue and black irresistible and it feeds exclusively on blood.
    • Researchers hope to identify a tsetse-specific reproductive inhibitor that has no mammalian toxicity.
    • The tsetse fly has been in mammals' ointment for at least 34M years.
    • Sleeping sickness afflicts far fewer people than malaria and dengue.
    • In 2012 there were 7,216 recorded cases according to WHO, but the incidence is most certainly under-reported.
    • ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    • ETFs: IRY, IXJ
    | Apr. 25, 2014, 12:46 PM
  • Apr. 22, 2014, 12:14 PM
    | Apr. 22, 2014, 12:14 PM
  • Apr. 22, 2014, 11:33 AM
    • The FDA proposes an "Expedited Access PMA" (EAP) process for medical devices that treat or diagnose patients with serious conditions whose medical needs are unmet by current technology. The program features earlier and more interactive participation by agency staff to collaboratively develop a plan for the collection of the scientific and clinical data to support approval. The EAP aims to reduce certain devices' development times in addition to the expected shortened premarket review.
    • Eligible devices must fit the following profile: 1) be intended to treat or diagnose a life-threatening or irreversibly-debilitating disease or condition and 2) represent one of the following: no approved alternative treatment/diagnostic exists or it represents a breakthrough technology that provides a clinically meaningful advantage over existing technology or offers a significant clinically meaningful advantage over currently-available alternatives or the device's availability is in the patient's best interest.
    • The proposed EAP builds on the Expedited Access Program for pharmaceuticals that the FDA launched in 2011.
    • Draft guidance
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, XHE, PTH, DRGS, RXD
    | Apr. 22, 2014, 11:33 AM
  • Apr. 21, 2014, 12:56 PM
    • Three late bull market biotech IPOs are shining examples of the truism of sector rotation and the value of diving through the funding window before it closes.
    • Ultragenyx Pharmaceutical (RARE -6.4%) debuted on January 31 on robust volume of 4.4M shares. Trading opened at almost 2x the IPO price of $21 ending the day at $42.25. Prices peaked at $69.77 on March 13. Shares trade hands today at $40. The firm still sports a market cap of $1.2B despite no revenues and two products in Phase 2 clinicals.
    • Dicerna Pharmaceuticals (DRNA -1.5%) debuted on January 30 on 4M shares. Trading opened at > 2x the IPO price of $15 ending the day at $46 never to return. Today shares exchange hands at $16, a tidy 65% drop from the peak. The company has no revenues and only one product in Phase 1 clinicals.
    • Uniqure N.V. (QURE -1%) debuted on February 5 on 4.7M shares. Prices struggled to stay above the IPO price of $17 and eventually succumbed to selling pressure ending the day at $14.61. Prices peaked at $18.75 on February 26. Shares trade hands today at $8.80 representing a 53% haircut from the peak. The company has no product revenues but plans to launch its gene therapy product, Glybera, in selected European countries in H1 2014.
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Apr. 21, 2014, 12:56 PM | 1 Comment
  • Apr. 17, 2014, 1:30 PM
    • Scientists create patient-specific cell lines from the skin cells of two adult men in a procedure called somatic cell nuclear transfer demonstrating that the technique can work for people of all ages. The embryonic cells are genetically identical to the donor and have profound therapeutic potential.
    • The cloning procedure is difficult, however. Only one in thirty-nine attempts was successful.
    • In therapeutic cloning, a jolt of electricity fuses a grown cell (e.g. skin cell) with an ovum whose DNA has been removed. After ~5 days of dividing and multiplying it develops into a hollow sphere-shaped embryo. The interior cells are pluripotent stem cells which can develop into many different kinds of cells. The goal is to coax them to develop into specialized cells for therapeutic purposes.
    • Complicating the ability to create patient-specific cell lines for millions of people are women's reticence over donating eggs, a sometimes painful process. Widespread donations may not be ultimately necessary since many people have genetically similar immune systems so 100 human embryonic stem cell lines would match over 50% of the U.S. population according to the co-author of the study, Dr. Robert Lanza.
    • Healthcare ETFs: IYH, IBB, XLV, XBI, VHT, BIB, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, IRY, IXJ, PPH, IHI, BIS, IHF, FHLC, XHS, PSCH, RYH, PTH, XHE, DRGS, RXD
    | Apr. 17, 2014, 1:30 PM
  • Apr. 17, 2014, 8:04 AM
    • In a novel cancer study funded with $42M by Cancer Research UK, scientists will test up to 14 different cancer drugs at the same time within one clinical trial. The objective is to identify the most effective treatments for advanced lung cancer by targeting specific rare genetic mutations.
    • The new approach will select a range of drugs for a specific patient instead of designing a study around a specific drug. In a profound change it eliminates randomization, the hallmark of clinical trial design.
    • Some mutations occur on only 1% - 2% of patients so the traditional method of clinical trial design is too expensive, time-consuming and inefficient.
    • AstraZeneca (AZN) will supply up to twelve experimental drugs that will be given to patients who do not show one of twenty-one sets of genetic abnormalities.
    • Pfizer (PFE) will supply its lung cancer drug Xalkori plus the experimental breast cancer drug palbociclib.
    • About 15-20 patients will be involved in the trial. Those drugs that show no benefit will be quickly dropped while those showing efficacy will be fast-tracked into larger-scale testing.
    • Healthcare ETFs: IYH, IBB, XLV, XBI, BIB, VHT, PJP, BBH, FBT, PBE, XPH, CURE, FXH, IHE, RXL, PPH, BIS, FHLC, PSCH, RYH, PTH, DRGS, RXD
    | Apr. 17, 2014, 8:04 AM
  • Apr. 10, 2014, 3:03 PM
    • iShares NASDAQ Biotech Index (IBB -5.8%) continues its down trend today on a 50% spike in volume. The index has lost 20% of its value since its February 25 high of $275.40.
    • The index is now perched above the key support level of its 200-day moving average.
    • If this week's decline holds it will mark the seventh straight on high volume.
    • ETFs: XBI, BIB, BBH, FBT, PBE, BIS
    | Apr. 10, 2014, 3:03 PM | 15 Comments
  • Apr. 10, 2014, 11:09 AM
    | Apr. 10, 2014, 11:09 AM | 6 Comments
  • Mar. 24, 2014, 11:36 AM
    | Mar. 24, 2014, 11:36 AM | 5 Comments
  • Mar. 21, 2014, 10:49 AM
    • Biotech investors should be wary of the inevitable rotation of the industry. The iShares Biotech Index (IBB) is down 3.5% today on slightly higher volume. Money flow as been decidedly negative over the last three weeks.
    • The current price of $250 is testing support at its 10-week EMA. If it rebounds on robust volume then all is well.
    • Biotech's bull run began in early 2012.
    • ETFs: XBI, BIB, BBH, FBT, PBE, BIS
    | Mar. 21, 2014, 10:49 AM | 16 Comments
  • Feb. 24, 2014, 12:54 PM
    • Size alone is somewhat irrelevant in examining a particular market sector, says Bernstein's Geoffrey Porges, but at some point it needs to reflect future profit potential. The market value of the booming biotech sector has reached $582B, he says, putting the industry on par with chemicals, beverages, and heavy equipment manufacturers. Biotech is now worth more than the aerospace/defense companies and auto manufacturers combined, and is on its way towards the $600B+ territory of investment banks, semiconductor and related, and utilities.
    • Over the last two years, the value of biotech is up 128%, more than double the increase in pharma and medtech stocks, and 3x the growth in the overall market. In two years, biotech has added value greater than the total current value of the transportation industry, or of the metals mining industry, or of the auto industry.
    • Biotech's size along with the fast raising of capital (about the same as during the 1999-2001 boom) has Porges somewhat worried, and he thinks higher interest rates and a stumbling broader market could see the sector slumping up to 40%. His favorites to own are Celgene (CELG) and Gilead (GILD) because of strong cash flows and very low relative multiples.
    • Related ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Feb. 24, 2014, 12:54 PM | 10 Comments
  • Feb. 14, 2014, 11:35 AM
    | Feb. 14, 2014, 11:35 AM | 4 Comments
BBH Description
VanEck Vectors Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub